

1 **Title: Genome-wide DNA methylation-analysis delineates blastic plasmacytoid dendritic**  
2 **cell neoplasm from related entities and identifies distinct molecular features**

3

4 **Authors:** Axel Künstner<sup>1,2,\*</sup>, Julian Schwarting<sup>2,3,4\*</sup>, Hanno M. Witte<sup>2,3,5\*</sup>, Pengwei Xing<sup>6</sup>,  
5 Veronica Bernard<sup>4</sup>, Stephanie Stölting<sup>4</sup>, Philipp Lohneis<sup>4</sup>, Florian Janke<sup>7</sup>, Maede Salehi<sup>6</sup>,  
6 Xingqi Chen<sup>6</sup>, Kathrin Kusch<sup>4</sup>, Holger Sülthmann<sup>7</sup>, Emil Chteinberg<sup>8</sup>, Anja Fischer<sup>8</sup>, Reiner  
7 Siebert<sup>8</sup>, Nikolas von Bubnoff<sup>2,3</sup>, Hartmut Merz<sup>4</sup>, Hauke Busch<sup>1,2\*\*</sup>, Alfred C. Feller<sup>4\*\*</sup>,  
8 Niklas Gebauer<sup>2,3\*\*</sup>

9

10 **Affiliations:**

11 <sup>1</sup> Medical Systems Biology Group, University of Lübeck, Ratzeburger Allee 160, 23538  
12 Lübeck, Germany

13 <sup>2</sup> University Cancer Center Schleswig-Holstein, University Hospital of Schleswig-Holstein,  
14 Campus Lübeck, 23538 Lübeck, Germany

15 <sup>3</sup> Department of Hematology and Oncology, University Hospital of Schleswig-Holstein,  
16 Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany

17 <sup>4</sup> Hämatopathologie Lübeck, Consultation Centre for Lymph Node Pathology and  
18 Hematopathology, 23562 Lübeck, Germany.

19 <sup>5</sup> Department of Hematology and Oncology, Federal Armed Forces Hospital Ulm, Oberer  
20 Eselsberg 40, 89081 Ulm.

21 <sup>6</sup> Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala,  
22 Sweden.

23 <sup>7</sup> Division of Cancer Genome Research, German Cancer Research Center (DKFZ), 69120  
24 Heidelberg, Germany; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.

25 <sup>8</sup> Institute of Human Genetics Ulm University and Ulm University Medical Center, 89081  
26 Ulm, Germany.

27 **Scientific category: Myeloid Neoplasia**

28 **Running Title:** BPDCN methylome

29 **Key Words:** blastic plasmacytoid dendritic cell neoplasm, whole-exome sequencing, RNA-

30 sequencing, methylome, AML

31 **Word Count (Text): 6569 (incl. Materials and Methods)**

32 **Word Count (Abstract): 150**

33 **References: 76**

34 **Tables: 1**

35 **Figures: 6**

36 **Supplementary Tables: 5**

37 **Supplemental Figures: 7**

38 **Competing Interests:** The authors declare no conflicts of interest.

39

40 \*These authors contributed equally to this manuscript

41 \*\*Shared senior authorship

42 **Date of submission: 27.07.2023**

43 **Corresponding Author:**

44 PD Dr. med. Niklas Gebauer

45 Department of Hematology and Oncology

46 UKSH Campus Luebeck

47 Ratzeburger Allee 160

48 23538 Luebeck

49 Email: [Niklas.Gebauer@uksh.de](mailto:Niklas.Gebauer@uksh.de)

50

51

52

53 **Abstract:**

54 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) constitutes a rare and aggressive  
55 malignancy originating from plasmacytoid/common dendritic cells (pDCs/cDCs) with a  
56 primarily cutaneous tropism followed by dissemination to the bone marrow and other organs.  
57 We conducted a genome-wide analysis of the tumor methylome in an extended cohort of 45  
58 BPDCN patients supplemented by WES (n=54) and RNA-seq (n=54) as well as ATAC-seq  
59 on selected cases (n=4). We determine the BPDCN DNA methylation profile and thereby  
60 identify a reliable means to discriminate BPDCN from AML, CMML and T-ALL. DNA  
61 methylation profiling characterizes disruption of oncogenic pathways whilst unraveling the  
62 proliferative history as well as the prognostically relevant composition of the tumor  
63 microenvironment. Beyond the two recently established BPDCN subtypes (C1/C2), we  
64 identified a transcriptional reliance on JAK/STAT and NFκB-signaling in atypical C2 versus  
65 C1-BPDCN cases through RNA-sequencing. Our integrative characterization of BPDCN  
66 offers novel molecular insights and potential diagnostic applications.

67

68 **Introduction:**

69 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and extremely rare  
70 blood cancer, accounting for approx. 0.5% of acute hematological malignancies. In its recent  
71 editions, the WHO classification of myeloid neoplasms recognizes BPDCN as a distinct entity  
72 descending from non-activated, CD56<sup>+</sup> plasmacytoid dendritic cells (pDC) <sup>1, 2, 3</sup>. However, a  
73 broader cellular origin encompassing transcriptional signatures of both AXL1<sup>+</sup> SIGLEC6<sup>+</sup>  
74 DCs and earlier, common dendritic cells, termed AS-DCs and cDCs, respectively, has been  
75 proposed, before, suggesting a diverse cellular ontogeny <sup>4, 5, 6</sup>. Clinically, skin lesions  
76 commonly precede bone marrow infiltration and secondary propagation into lymph nodes and  
77 extranodal organs. A striking 4:1 male predominance, attributed to sex-biased *ZRSR2*  
78 mutations and enrichment in elderly patients with a median age of around 70 years at

79 diagnosis has been observed <sup>7,8</sup>. While the typical BPDCN immunophenotype (CD4<sup>+</sup>, CD56<sup>+</sup>,  
80 CD123<sup>+</sup>) is relatively specific and reliably enables correct diagnosis, discrimination from  
81 AML, especially cases with pDC features can be challenging <sup>9, 10</sup>. Investigation of pDC-  
82 associated antigens (e.g., TCL1 or CD303) can further facilitate differential diagnosis, while  
83 the expression of B- (CD79b), T- (CD2, CD7) and precursor antigens (Tdt) poses variable  
84 pitfalls <sup>11</sup>. Treatment with conventional chemotherapy alone results in insufficient and short-  
85 lived remissions (median overall survival (OS) of 12 to 14 months), which necessitates either  
86 allogeneic or autologous stem cell transplantation (SCT) in therapeutic approaches of curative  
87 intent <sup>7, 12, 13</sup>. Only through the introduction of tagraxofusp, a CD123-directed cytotoxin,  
88 which recently demonstrated high clinical efficacy, curative treatment has become possible in  
89 elderly patients, as well, while the outcome in relapsed/refractory cases remains dismal <sup>14</sup>.

90 Genome-wide DNA methylation profiling has evolved from a descriptive, ontological  
91 analysis into a diagnostic assay of prognostic relevance across a variety of solid cancers,  
92 including CNS tumors and sarcomas <sup>15, 16</sup>. While genomic and transcriptional profiling has  
93 revolutionized the taxonomy of myeloid cancers, embedded in the current WHO  
94 classification, the study of DNA methylation may add another layer of insight into BPDCN  
95 biology that is so far insufficiently captured by DNA- and RNA-sequencing <sup>1</sup>. Methylome  
96 analysis may further assist in differential diagnostics between BPDCN and other malignancies  
97 sharing close molecular ties including chronic myelomonocytic leukemia (CMML), acute  
98 myeloid leukemia (AML) and myelodysplastic syndromes (MDS), which may occur syn- and  
99 metachronously in up to 20% of cases <sup>17</sup>.

100 DNA methylation profiling can further assess the tumor immune microenvironment (TME),  
101 by deconvoluting cell types from within tissue-derived bulk DNA and discriminating  
102 immunologically hot from cold tumors <sup>18</sup>. The robust correlation of its output with an  
103 immunohistochemical dissection of the TME has been shown in non-small cell lung cancer  
104 and others <sup>18, 19</sup>.

105 In this study, we have extended our previously published BPDCN cohort<sup>6</sup>, assessed by paired  
106 whole-exome (WES) and RNA-sequencing (RNA-seq) as well as genome-wide copy number  
107 analysis and conducted array-based genome-wide DNA methylation profiling and ATAC-  
108 sequencing on selected cases, allowing for a more profound and novel understanding of  
109 BPDCN pathobiology and reliable discrimination from AML as the predominant diagnostic  
110 challenge in clinical practice. Moreover, we identify two immunological subtypes,  
111 characterized by features in the TME and recurrent genomic alterations.

112

## 113 **Results**

### 114 **Clinical characteristics of the study group and expanded deconvolution cohort**

115 We collected 54 quality controlled (diagnostic BPDCN samples with sufficient formalin-fixed  
116 paraffin-embedded (FFPE) tissues (age range 15 – 91 years; mean/median 69/72 years). We  
117 observed an expectedly strong male predominance (40/54; 74%) and uniform cutaneous  
118 involvement alongside a pronounced proclivity for extranodal involvement. Of patients in  
119 first complete (CR) or partial remission (PR), 24% went on to autologous/allogeneic SCT.  
120 Clinical outcomes, when available, reflected previous dismal observations in BPDCN with a  
121 median progression-free and overall survival of eight and twelve months, respectively. Best  
122 supportive care was provided in four cases where any form of anti-neoplastic treatment was  
123 refused.

124 BPDCN-specific markers were expressed in all cases, whereas precursor antigens (CD34,  
125 TdT) were present in 5/47 (11%) and 34/47 (72%) respectively. Baseline clinicopathological  
126 characteristics of BPDCN cases included in the current study are briefly summarized in **Table**  
127 **1**. In accordance with our previous study, RNA-seq data were deconvoluted according to  
128 single-cell DC and monocyte datasets and previous observations were recapitulated/extended  
129 to new samples including differentially mutated genes (**Supplementary Figures 1 and 2**).

130 Additionally, mutational landscape and MutSigCV analysis were extended to new cases as  
131 previously described (**Supplementary Tables 1 and 2**)<sup>6</sup>. Tumor mutational burden (TMB)  
132 was confirmed to be significantly higher ( $p = 0.0055$ ) among C1-BPDCN and an updated set  
133 of differentially mutated genes was identified (**Supplementary Figures 3a and 3b**).

134

### 135 **Epigenetic profiling reveals significant deregulation of key regulatory pathways through** 136 **loss of DNA methylation compared to dendritic cells**

137 In order to assess epigenetic processes contributing to the malignant transformation from DCs  
138 to BPDCN and to allocate the entity within the spectrum of blood cells, we performed a  
139 principal component analysis (PCA) of BPDCN and various cell types of the peripheral blood  
140 (**Figure 1**)<sup>20</sup>. Expectedly, we observed a clear segregation of blood cell types and BPDCN,  
141 but beyond this, a marked difference between BPDCN and previously profiled DC subsets  
142 became apparent (**Figure 1a**)<sup>21</sup>. This was further reflected in significantly higher global mean  
143 DNA methylation levels in both early and more mature DCs, signifying the dramatic extent of  
144 DNA methylation loss during malignant transformation of DCs towards BPDCN (**Figure 1b**).  
145 An enrichment analysis of differentially methylated regions (CpG FDRs < 0.01, absolute  
146 difference above 0.3, enrichment analysis against HALLMARK and REACTOME gene sets)  
147 revealed significantly reduced DNA methylation in candidate genes involved in processes like  
148 extracellular matrix organization, collagen modulation and the neuronal system as recently  
149 implicated in BPDCN pathobiology<sup>22</sup>. Moreover, potentially oncogenic driver processes  
150 affected by these altered profiles included KRAS signaling and the interaction with the  
151 extracellular matrix (**Figure 1c, d**).

152

153 **BPDCN is characterized by a DNA methylation profile distinct from its related entities**  
154 **yet borderline cases exist.**

155 To assess the potential of DNA methylation analysis in the differential diagnosis between  
156 BPDCN and AML as well as CMML, we performed a comparative analysis of DNA  
157 methylation data between our cohort and a previously published cohort of AML patients,  
158 representing all relevant molecular subtypes, reanalyzing the BEAT-AML cohort as well as a  
159 CMML cohort previously published by Palomo *et al.* This analysis revealed a separation of  
160 samples into entity-specific DNA methylation classes in both an unsupervised (PCA; **Figure**  
161 **2a**) as well as a supervised (PLS-DA; **Figure 2b**) approach. Distinction from T-cell acute  
162 lymphoblastic leukemia (T-ALL) and malignant melanoma, which was added for comparison,  
163 as another entity originating in the skin, driven by a UV-related mutational signature, was  
164 even more pronounced (**Figure 2j**). Intriguingly, we observed four borderline cases through  
165 our DNA methylation-based classification (**Figure 2c**; BPDCN\_01; 15; 27; 37), exhibiting a  
166 relevant amount of overlap between both groups in terms of DNA methylation. In contrast to  
167 the overall clear distinction between BPDCN and AML, we found three of these cases to  
168 exhibit synchronous concurrent manifestations of AML and/or transformed CMML with pDC  
169 features and one of these three cases even presented with genetic features typically  
170 encountered in AML with pDC-features (e.g., a *RUNX1* mutation; **Figure 2c, d-i**). The one  
171 patient allocated closest to the 95% CI cut-off for the AML definition by our analysis,  
172 exhibited a typical pDC-like C1-BPDCN phenotype, while the other, more pronounced  
173 borderline classified cases were C2 cases, exhibiting a more immature DC phenotype with  
174 fractional monocyte signatures. Subsequent comparative pathway enrichment analysis against  
175 HALLMARK and REACTOME gene sets for most differentially methylated regions (DMRs)  
176 within gene-body regions revealed a significant enrichment across RHO GTPases, cell  
177 migration control and leukemic stem cell maintenance (via HSF1 activation) in BPDCN,  
178 whereas promotor regions in BPDCN compared to AML were methylated to a significantly  
179 higher degree in epigenetic and transcriptional regulation as well as TP53 regulation and cell  
180 cycle control. (**Figure 2m-o**).

181

182 **The BPDCN genome is characterized by an exceptional degree of DNA methylation loss**  
183 **and epigenetic signs of mitotic stress**

184 Global DNA methylation is commonly diminished in malignant compared to healthy cells,  
185 being stably maintained in the latter. In this line, BPDCN revealed even the highest  
186 methylation loss compared to other blood cancers, including AML, CMML, and T-ALL<sup>23, 24,</sup>  
187 <sup>25</sup>. Global methylation levels in BPDCN even fall below that of melanoma, irrespective of the  
188 C1 or C2 subtype (Wilcoxon rank-sum test,  $p < 0.001$ ). Melanoma was chosen for  
189 comparison because of its origin from UV-light exposure in the skin and the ensuing overlap  
190 in the mutational signatures (**Figure 2k**)<sup>8, 26</sup>; transcriptional BPDCN subtype (C1 vs C2) did  
191 not affect this. Intriguingly, the aggressive clinical nature of BPDCN was further reflected in  
192 our observations made through the application of epiCMIT, a DNA methylation-based mitotic  
193 clock, which recapitulates the proliferative history of a given tumor sample<sup>27</sup>. epiCMIT  
194 predicted a significantly accelerated mitotic history in BPDCN compared to CMML and even  
195 AML, matched only by T-ALL (**Figure 2l**). Although an independent prognostic impact of a  
196 high epiCMIT score was observed for a wide range of blood cancers, we observed no such  
197 trend in our cohort, plausibly attributable to the limited sample size.

198

199 **DNA methylation of tumor suppressor genes is highly deregulated in BPDCN compared**  
200 **to CMML and AML.**

201 In keeping with a substantially deregulated DNA methylation profile in BPDCN and a global  
202 loss of DNA methylation, we observed promotor regions of tumor suppressor genes to be  
203 methylated to an exceptionally high degree, compared to CMML and even AML (**Figure 3a**).  
204 At the same time a significantly lower level of gene-body associated methylation in the same



205 genes was identified, again in comparison with CMML and even AML (**Figure 3b**),  
206 indicating a substantial oncogenic impact of deregulated DNA methylation in BPDCN  
207 (manually selected candidate TSGs, **Figure 3c**, for exhaustive information on deregulated  
208 TSGs see **Supplementary Figure 2**). Strikingly, we hereby observe an increasingly  
209 deregulated DNA methylation profile from CMML to BPDCN in parallel to the  
210 aggressiveness of the entity's clinical behavior, ranging from the rather indolent and slowly  
211 progressing course of CMML in comparison to the more aggressive clinical presentation of  
212 AML, which is even more pronounced in BPDCN.

213

#### 214 **Differential DNA methylation patterns and gene expression signatures differentiate C1** 215 **and C2 subtypes in BPDCN and shape a JAK/STAT-driven profile in C2-BPDCN**

216 Building on our previous BPDCN subtype classification, we performed a differential DNA  
217 methylation analysis. Alongside differentially mutated genes in BPDCN, we discovered 114  
218 probes, which were differentially methylated between C1 and C2 ( $p < 0.0001$ ; 10,136 probes  
219 with  $p < 0.01$ ), corresponding to a relatively similar methylome, in keeping with our above  
220 PCA/PLS-DA (depicted as scales beta values in **Figure 4a**; beta values see **Supplementary**  
221 **Table 4**).

222 Subsequently, to gain insight into the effect of differential DNA methylation on the  
223 phenotypical development of both subtypes, we assigned differentially methylated probes to  
224 their respective genes (**Figure 4b**). Gene set testing (GST) (**Figure 4c**) revealed enrichment in  
225 elevated DNA methylation levels for interleukin signaling genes as well as prominent  
226 members of JAK/STAT signaling (including STAT5B) in C1-BPDCN, whereas C2-BPDCN  
227 samples exhibit significantly pronounced DNA methylation of posttranslational modifications  
228 like glycosylation and metabolic processes (e.g., vitamin and heme metabolism).

229 Expanding on our differential assessment of C1 and C2-BPDCN onto the transcriptional  
230 level, we performed differential gene expression analysis (**Figure 4d, e**). Hereby, we  
231 observed an induction of innate and adaptive immunological processes alongside an  
232 upregulation of extracellular matrix-interactions in C2 cases by gene set enrichment. Further,  
233 we found several prominent candidate genes, including *STAT5A*, *CDK6*, *CCR4*, *CCND2* and  
234 *FOXO1* to be expressed at significantly higher levels in atypical C2 cases. Corresponding to  
235 higher gene expressions in C2, *CDK6* ( $p = 5.3 \times 10^{-4}$ ,  $\log_2$  fold-change 1.52) and *STAT5A* ( $p =$   
236  $5.5 \times 10^{-3}$ ,  $\log_2$  fold-change 1.19) had promotor-associated sites that were significantly higher  
237 methylated in C1-BPDCN leading to relative transcriptional inactivation in C1. Correlation of  
238 DNA methylation and relative RNA-seq derived gene expression data yielded a substantial  
239 number of significant correlations among TSGs and oncogenes including *BCL2*, *STAT5A* and  
240 *SOX1* (**Supplementary Table 5a**). Upon extension of the analysis unto the entire  
241 transcriptome further significant correlations ( $q < 0.1$ ) were observed (**Supplementary Table**  
242 **5b**).

243 In order to further focus our observations on potential therapeutic applicability, we inferred  
244 transcription factor (TF) activities from bulk RNA-seq data employing CollecTRI as a  
245 resource for TF<sub>i</sub> pathway activity inference with PROGENy. Hereby we observed the  
246 transcriptional mirror image of the divergence in DNA methylation profiles between C1 and  
247 C2-BPDCN. In particular, we observed significantly higher activity of NFκB (driven by  
248 FOXC1, NFKB1 and NFKB;  $p < 0.05$ ) and more strikingly JAK-STAT (predominantly  
249 driven by STAT3, STAT1 and STAT5A;  $p < 0.05$ ) associated TF in C2 and an EZH2  
250 dependence in C1-BPDCN (**Figure 4f, g**). In addition, we supplemented these observations  
251 by FFPE-ATAC-seq of four C2-BPDCN, which revealed substantial chromatin accessibility,  
252 in keeping with our epigenetic and transcriptional findings (**Figure 4h, i**).

253

254 **Cellular composition of the tumor microenvironment by MethylCIBERSORT and**  
255 **immunohistochemistry reveals distinct immunological subtypes correlated with tumor**  
256 **genomics**

257 In order to evaluate the composition of the tumor microenvironment (TME), we conducted a  
258 MethylCIBERSORT analysis on all 45 high-quality genome-wide DNA methylation profiles  
259 from primary diagnostic samples. From the inferred relative abundance of T cells and their  
260 respective subpopulations (CD4<sup>+</sup> effector cells, CD8<sup>+</sup> cytotoxic cells, regulatory T cells  
261 (Tregs)) alongside B-cells, natural killer (NK)-cells neutrophils, monocytes, eosinophils and  
262 stromal cells (fibroblasts, endothelial cells) two TME classes (IC1 and IC2) were predicted.  
263 The smaller class (IC1) exhibited a depletion in monocytes, B- and NK-cells, an enrichment  
264 in Tregs and a trend towards higher counts of neutrophils and cytotoxic T cells (**Figure 5a**).  
265 These observations were subsequently validated via IHC for tumor-infiltrating T cells and  
266 monocytes with a significant correlation between relative distributions of cell populations  
267 according to the respective methodology (**Figure 5b – e, g, h**). Comparing IHC and  
268 MethylCibersort estimates, we found a significant correlation in monocytes (Pearson  
269 correlation coefficient = 0.6437,  $p = 1.84 \times 10^{-6}$ ) and in T-cell populations (Pearson correlation  
270 coefficient = 0.3809  $p = 0.0098$ ). Beyond a statistical trend towards an overall higher TMB,  
271 we observed an enrichment in mutations affecting *ERBB2*, *ASXL1*, *EP300* and *KMT2C*  
272 mutations. Further, we identified more frequent mutations in *CDH1*, *JAK2*, *SMAD2*,  
273 *NOTCH1* and *DNMT3A* (**Figure 5 f**). Patients in the IC1 subgroup had a significantly shorter  
274 progression-free survival ( $p = 0.039$ ) and a trend towards inferior overall survival ( $p = 0.14$ )  
275 in IC1 patients (**Figure 5 i, j**). Correlating the results from our MethylCIBERSORT approach  
276 with the genomic landscape of BPDCN (restricted to on genes mutated in at least 30% of  
277 cases;  $n = 8$ ), mutations in *EP300*, *KMT2C* and *NOTCH2* were associated with a significant  
278 enrichment of eosinophils (*KMT2C*:  $p = 0.038$ ), monocytes (*EP300*:  $p = 0.045$ ; *NOTCH2*:  $p =$

279 0.0026), CD4 effector cells (*EP300*:  $p = 0.042$ ) and regulatory T-cells (*EP300*:  $p = 0.012$ )  
280 within the TME, respectively (**Supplementary Figure 4**). Previous reports identified a strong  
281 correlation between DNA methylation and chronological age<sup>28, 29</sup>. Based on our  
282 MethylCIBERSORT results leading to the allocation of two clusters, epiCMIT was applied to  
283 estimate the history of proliferative stress/DNA<sub>m</sub> age. In contrast to the  
284 genome/transcriptome-based BPDCN clusters C1/C2 (**Figure 2I**), the immunological cluster  
285 IC2 showed a DNA methylation imprint of significantly higher proliferative stress compared  
286 to IC1, which resembles DNA methylation-based pre-aging in this subgroup ( $p = 0.038$ ;  
287 **Supplementary Figure 5**).

288 In keeping with the higher levels of DNA methylation and the subsequently suppressed  
289 expression of adaptive immunological processes in typical pDC-like C1-BPDCN cases, we  
290 observed a trend towards higher levels of tumor-infiltrating T-cells in C2-BPDCN samples  
291 despite the overall higher TMB in C1 patients, regardless of patient age or location of the  
292 tumor sample by both MethylCIBERSORT and IHC (**Supplementary Figure 6a, b**).

293

## 294 **DNA methylation-based clusters cannot be fully recapitulated in transcriptional BPDCN** 295 **subtypes**

296 The most 5,600 variable CpG probes were subject to discovering DNA methylation subtypes  
297 using K-means clustering. The optimal number of clusters was determined using the average  
298 silhouette method and gap statistics. Both methods agreed on the optimal number of clusters  
299 ( $n = 2$ ). Upon unsupervised cluster analysis, we observed no statistically significant  
300 recapitulation of transcriptional BPDCN subtypes C1 and C2 in the methylome. Some overlap  
301 was, however, found in shared genomic features (*EP300* and *ATRX* mutations in C1 and  
302 MethC1), consistent with higher TMB in C1 and MethC1. A significantly more pronounced

303 overlap was apparent upon correlation analysis between DNA methylation-based cluster  
304 allocation and immunological clusters according to our methyCIBERSORT-derived  
305 immunoclusters (**Supplementary Figure 7a,b**).

306

### 307 **Mutational drivers and promotor status of epigenetic regulators shape the proliferative** 308 **fate and DNA methylation profile of BPDCN**

309 In order to provide a genomic context for the DNA methylation profiles obtained within this  
310 study, we performed WES on all patients, who were not part of our previous molecular  
311 landscape project in BPDCN, which led to the most comprehensive mutational  
312 characterization of any BPDCN cohort to date (**Figure 6a**). WES of our extended BPDCN  
313 cohort identified a higher mutational load compared to the C2 cluster. This further supports  
314 the assumption of another non-mutational mechanism driving in C2-BPDCN such as a  
315 deregulated DNA methylation and transcriptional profile outlined above. The exceptional  
316 pathophysiological role of epigenetic features within the C2 cluster is supported by more  
317 frequent *DNMT3A* alterations bordering on statistical significance in this limited cohort and  
318 the significant deregulation of splicing genes such as *SRSF2*.

319 Following mutational characterization, we wondered whether specific mutational drivers were  
320 associated with the proliferative history of a given case, thereby integrating mutational and  
321 epigenetic datasets in order to identify genetic alterations, which could confer a selective  
322 advantage as mitotic accelerators in BPDCN cells. While definitive conclusions are  
323 complicated by the limited sample size, we observed a trend towards a proliferative increase  
324 in cases harboring *ARID1A*, *ZRSR2*, *JAK3*, *CIC* and *CREBBP* mutations and a (significant)  
325 decrease in mitotic activity in cases affected by mutations in *PPARGC1A*, *CDH1*, *SI*, *RUNX1*,  
326 *SF3B1*, *MSH2* and *SETD2* (**Figure 6b, c**). In summary, our findings suggest, that the

327 proliferative potential of BPDCN is determined by certain mutational driver events.

328 In order to unravel additional determinants, which shape the overall strongly demethylated  
329 landscape in BPDCN, we investigated the promotor DNA methylation status of a set of genes  
330 associated with epigenetic regulation (**Figure 6d**). Hypermethylation of the promotor region  
331 (promoter CGI methylation  $>0.2$ ) of *DNMT1*, *WT1*, *MYC* and *TET1* was hereby observed in  
332 42.2%, 73.2%, 40.0% and 53.3% of patients respectively. Further, we observed a significant  
333 correlation between promotor methylation and overall CGI methylation for 22 of the 24 genes  
334 (Spearman's rank correlation,  $p_{\text{adj}} < 0.05$ ) signifying a substantial impact on the epigenetic  
335 landscape in BPDCN. Only DNMT1 and KMD2B did not show a significant correlation. Of  
336 note, a substantial overlap between patients harboring *WT1* and *MYC* promoter methylation  
337 was observed 16/45 cases (35.6%). Given that *MYC* constitutes a known *WT1* target, this  
338 hints at a coupled mechanism of both genes in BPDCN pathogenesis<sup>30</sup> (**Figure 6b, c**).

339

## 340 **Discussion**

341 BPDCN is a clinically and molecularly heterogeneous disease that poses a multi-level  
342 challenge in terms of diagnostics and treatment alike. Unraveling the epigenetic  
343 characteristics of the disease may pose an aid in providing a correct and timely diagnosis,  
344 which is crucial for the initiation of specific treatments. Through a comparative analysis of  
345 the DNA methylation landscape of BPDCN incorporating related hematological malignancies  
346 (AML, CMML and T-ALL patients, encompassing all relevant genetic and phenotypical  
347 subgroups), we identify distinguishing features and provide unprecedented insights into the  
348 molecular pathogenesis of BPDCN, which may in term facilitate the development of more  
349 refined targeted therapeutic approaches. In this integrated molecular study of BPDCN we  
350 report on the largest cohort studied so far. Where previous reports on BPDCN were limited by

351 small cohorts and restricted methodological approaches, we systematically defined genomic  
352 and transcriptional signatures in the context of genome-wide DNA methylation<sup>4, 8, 10, 31, 32, 33,</sup>  
353<sup>34, 35, 36, 37</sup>. Hereby, we made three novel and essential observations.

354 First, our study of DNA methylation profiles allowed for a clear distinction between globally  
355 demethylated BPDCN patient samples with only localized DNA hypermethylation showing  
356 dominant signs of mitotic stress, resembling a pronounced variant of the canonical cancer  
357 methylome on the one hand and AML, CMML as well as T-ALL on the other. In keeping  
358 with previous assumptions, we find enrichment in cases with distinct DNA hypomethylation,  
359 predominantly affecting late-replicating regions and molecular signs of extensive past mitotic  
360 stress<sup>38</sup>. Several patients, for whom a borderline DNA methylation profile between AML and  
361 BPDCN was identified, were found to resemble cases with either syn- or metachronous  
362 development of CMML/AML or a molecular and phenotypical constellation resembling AML  
363 with pDC-like features<sup>9, 10</sup>. Moreover, we observed all but one of these cases to exhibit the  
364 atypical, more immature cDC-impacted C2-BPDCN transcriptional profile<sup>6</sup>. This aligns with  
365 observations in B-cell malignancies and solid tumors where the DNA methylation profile  
366 reflects the degree of maturation of the cell-of-origin<sup>27, 39</sup>. Recently, clonal hematopoiesis of  
367 indeterminant potential (CHIP), disrupting epigenetic regulators in the majority of BPDCN  
368 cases, was proposed as an underlying mechanism rendering secondary mutations in RAS  
369 signaling (*NRAS*, *KRAS*) and tumor suppressors like *TP53* and *ATM* secondary clonal events  
370 and thereby more specific in BPDCN pathogenesis<sup>40</sup>. Our previous genomic studies revealed  
371 a significant overlap in mutational drivers between BPDCN and the abovementioned entities,  
372 underscoring the close molecular relatedness between BPDCN and especially AML/CMML,  
373 which was recently further illustrated in cases of divergent clonal evolution from a CHIP  
374 constellation. The present study of DNA methylation signatures, however, revealed a  
375 significant impact on signaling processes ultimately contributing to the specific phenotype of

376 BPDCN in particular. This can therefore be harnessed as a reliable discriminator beyond  
377 established immunophenotypical and histopathological approaches<sup>23, 41, 42</sup>. Moreover, DNA  
378 methylation profiling revealed a canonical epigenetic deregulation of TSGs with putative  
379 oncogenic effects, vastly exceeding previous observations in related entities<sup>23, 24</sup>.  
380 Intriguingly, we observed several mutational drivers of mitotic stress, signified through a  
381 proliferative epigenetic signature. In line with previously reported effects of *ARID1A*  
382 mutations on cell proliferation, we found *ARID1A* mutant BPDCN samples to exhibit  
383 pronounced signs of proliferative activity, while decreased mitotic activity in *RUNX1* mutant  
384 BPDCN is in keeping with reduced proliferation in hematopoietic stem cells harboring similar  
385 mutations<sup>43, 44</sup>. At the same time, unsupervised clustering of genome-wide DNA methylation  
386 levels only partially recapitulated transcriptional clusters, which was, however, previously  
387 observed in other blood cancers (e.g., T-ALL) as well<sup>45</sup>.  
388 Second, our recently established molecular subgroups of BPDCN differ in terms of both  
389 transcriptional profile by RNA-seq and to a lesser extent by DNA methylation signature.  
390 Confirming and expanding on previous studies, we found predominant pathways deregulated  
391 by these circumstances to include both innate and adaptive immunological processes, for  
392 which gene expression was significantly induced in C2-BPDCN cases. This corresponds well  
393 to elevated DNA methylation levels in interleukin/inflammatory signaling genes in C1-  
394 BPDCN, leading to a relative up-regulation of the interleukin 4/13 interactome in C2-BPDCN  
395<sup>46</sup>. Interrogating our bulk RNA-seq data for TF activity, we observed the transcriptional  
396 mirror image of the divergence in DNA methylation profiles between C1 and C2-BPDCN. Of  
397 particular interest, regarding potential therapeutically targetable vulnerabilities, we observed  
398 significantly higher activity of NFκB (driven by *FOXC1*, *NFKB1* and *NFKB*) and more  
399 strikingly, JAK-STAT (predominantly driven by *STAT3*, *STAT1* and *STAT5A*) associated TF  
400 activity in C2 in contrast to an *EZH2* dependence in C1-BPDCN. Potent and clinically well-  
401 tested inhibitors for potential molecularly informed therapeutic combinations with



402 tagraxofusp are readily available<sup>47</sup>. These observations were then verified by FFPE-ATAC-  
403 seq, which revealed substantial chromatin accessibility at highly expressed loci, including  
404 *CDK6* and *STAT5A*, in keeping with our epigenetic and transcriptional findings.

405 Finally, we gained insight into the tumor immune microenvironment through the combined  
406 analysis of MethylCIBERSORT and immunohistochemistry. The essential finding was that  
407 there are two, prognostically relevant immunologic clusters (IC1 and IC2) in BPDCN,  
408 characterizing the unfavorable IC1 subgroup (comprising approx. 25% of patients) harboring  
409 a trend towards a higher TMB and significant enrichment for *ERBB2*, *ASXL1*, *EP300* and  
410 *KMT2C* mutations alongside a TME relatively depleted of NK-cells, monocytes and B-cells  
411 but enriched in Tregs. A previous report raised the issue of immunotherapeutic approaches in  
412 BPDCN immunohistochemically investigating PD-L1 expression levels<sup>48</sup>. Our  
413 comprehensive MethylCIBERSORT approach identified a relevant subset of immunologic  
414 hot cases in which immunotherapeutic strategies seem to be promising in light of lacking  
415 treatment options beyond tagraxofusp<sup>48</sup>. Moreover, we found that IC2 had a significantly  
416 higher epigenetic age but there was no difference regarding chronological age between both  
417 subgroups. This is congruent with previous observations in NSCLC<sup>19</sup>, where it was  
418 hypothesized that a higher epigenetic age was able to emulate the malignant potential of  
419 tumors with a high mutational load or decisive driver mutations such as *TP53*. However, the  
420 authors went on to demonstrate that a higher epigenetic age was associated with favorable  
421 survival compared to tumors characterized by genomic instability and high mutational  
422 loads<sup>19</sup>. In addition to the immunologically defined clusters, we observed an elevated level of  
423 TILs in atypical C2-BPDCN. Our future goal is now to dissect the TME in even greater detail  
424 by single-cell RNA sequencing and spatial transcriptomics.

425 Limitations of the current study include a restricted number of cases alongside a partial lack  
426 of information on clinical follow-up for about half of the cohort. Additionally, a substantial

427 subset of tagraxofusp-treated patients will make a valuable addition to future studies.

428 In conclusion, employing an integrated molecular approach, we are able to reliably  
429 distinguish BPDCN from its related entities and identify clinical and molecular borderline  
430 cases. Further, we unravel the epigenetic and transcriptional underpinnings of our two  
431 recently defined subtypes of BPDCN, identifying divergent potential targetable vulnerabilities  
432 and characterizing immunologically and prognostically meaningful subtypes through DNA  
433 methylation profiling-derived quantitative TME assessment validated by  
434 immunohistochemistry.

435

## 436 **Methods**

### 437 **Case selection, clinicopathological assessment, whole exome, and whole transcriptome** 438 **sequencing**

439 For this retrospective analysis, we reviewed our institutional archive for cases of  
440 histologically confirmed BPDCN between January 2001 and April 2022. The study was  
441 approved by the ethics committee of the University of Lübeck (reference-no 18-311) and  
442 conducted in accordance with the declaration of Helsinki. Patients at the Consultation Center  
443 for Hematopathology provided written informed consent regarding routine diagnostic and  
444 academic assessment, including genomic studies. Histopathological work-up was performed  
445 as described<sup>6</sup> and yielded 74 cases of BPDCN, 54 of which had sufficient FFPE tissue  
446 samples available for subsequent molecular analysis were selected and subjected to a  
447 comprehensive immunophenotypic workup (47 samples were included in a previously  
448 published investigation of the mutational landscape in BPDCN<sup>6</sup>). Genomic DNA and RNA  
449 were extracted from three 5µm FFPE tissue sections of either tumor or normal tissue (where  
450 available; n = 3) employing Maxwell® RSC DNA FFPE kit and Maxwell® RSC RNA FFPE  
451 kit (both Promega). WES and RNA-Seq following library preparation using Agilent

452 SureSelect Human All Exon V6 library preparation kit (Agilent Technologies) and  
453 NEBNext® UltraT Directional RNA Library Prep Kit (New England BioLabs), respectively  
454 were performed on a NovaSeq platform (Illumina) at Novogene (UK) Co. as described <sup>49</sup>.  
455 Tumor whole exome libraries were sequenced to a median depth of 131x (mean 134 ± 52 s.d.)  
456 and normal libraries reached a median depth of 67x (mean 83 ± 36 s.d.).

457

#### 458 **Whole exome data processing and variant calling**

459 Sequencing data from WES was processed using the same workflow as previously described  
460 <sup>6</sup>. Briefly, raw reads (paired-end fastq format) were trimmed (adapter and quality values)  
461 applying FASTP (v0.23.0; minimum length, 50 bp; maximum unqualified bases, 30%; trim tail  
462 set to 1)<sup>50</sup>; trimmed reads were mapped to GRCh38 using bwa mem (v0.7.15)<sup>51</sup> and mappings  
463 were converted into BAM format using PICARD TOOLS (v2.18.4). Next, mate-pair information  
464 was fixed, PCR duplicates were removed, and base quality recalibration was performed using  
465 PICARD TOOLS, GATK (v4.2.3.0)<sup>52</sup> and dbSNP v138 <sup>53</sup>. Single nucleotide variants (SNVs)  
466 and short insertions and deletions (indels) were identified following GATKs best practices for  
467 somatic mutation calling (matched normal-tumor mode for samples with normal tissue  
468 available (n=3) and tumor-only mode for samples without normal tissue available). MUTECT2  
469 (GATK)<sup>54</sup> was applied to the processed mappings with GNOMAD variants as germline  
470 resource and the b38 exome panel from the 1000 genome project as a panel of normal,  
471 capturing the expected repertoire of germline variants to be expected in a Central European  
472 study population. Next, FFPE read orientation artifacts were identified and removed  
473 according to GATK guidelines. Filtered variants were annotated using VARIANT EFFECT  
474 PREDICTOR<sup>55</sup> (VEP v103, GRCh38; adding CADD v1.6, dbNSFP v4.1a23, and GNOMAD  
475 r3.0 as additional resources) and annotations were converted into *MAF* format using VCF2MAF  
476 (V1.6.21) (DOI:10.5281/ZENODO.593251); coverage was extracted directly from the vcf  
477 INFO field. The top 20 frequently mutated genes (FLAGS)<sup>56</sup> were removed from further

478 analysis and the remaining somatic variants were filtered as follows: minimum coverage of  
479 40, minimum alternative allele coverage of 5, minimum variant allele frequency of 10%, and  
480 only variants with a frequency  $< 0.1\%$  in 1000 genomes, GNOMAD, or ExAC were  
481 considered for subsequent downstream analysis. High-impact variants (CADD score  $> 10$ ) in  
482 tumor suppressors according to Vogelstein et al.<sup>57</sup> were filtered as such that minimum  
483 coverage of 20 minimum, minimum alternative coverage, and minimum variant allele  
484 frequency of 10% was required. Genes mutated more often than expected were identified by  
485 applying MUTSIGCV (v1.41)<sup>58</sup> and potential drivers were identified using  $p < 0.001$ . Tumor  
486 mutational burden (TMB) did not differ between tumor-only samples and samples with  
487 matched normal tissue at the finalization of the filtering process (Wilcox test,  $p = 0.1004$ ).

488

#### 489 **Transcriptome Data Processing, Quantification, Deconvolution, and Analysis**

490 Gene expression sequencing data were processed in the same manner as described previously  
491 <sup>6</sup>. Briefly, gene expression profiles were retrieved from adapter trimmed reads (FASTP as  
492 described above) using STAR ALIGNER (v2.7.4b)<sup>59</sup> against GRCh38 (GENCODE v37) as  
493 reference. On average 73.5 million reads (median 81.1) were successfully mapped to the  
494 human reference per tumor sample and 29.6 million reads (median 30.4) per normal sample,  
495 respectively. Count profiles were normalized applying MIXNORM (v0.0.0.9000; 50  
496 iterations, tolerance set to 0.1)<sup>60</sup>, which removes unwanted biological and technical effects  
497 from FFPE material that can bias the signal of interest. Differentially expressed genes on  
498 normalized expression values between two conditions were identified using a linear modeling  
499 approach (LIMMA package, v3.50.1)<sup>61</sup>.

500 Pathway enrichment analysis against REACTOME gene sets (MSIGDF R package v7.4) on  
501 significantly differentially expressed genes was performed using a rank-MANOVA-based  
502 approach as implemented in MITCH (v1.12.0; priority on significance)<sup>62</sup>; NF- $\kappa$ B pathway  
503 (KEGG) was added manually to the REACTOME gene set.

504 Previously published scRNA-data from Villani et al.<sup>63</sup> was used to infer the cell-type  
505 composition of the bulk RNA-Seq data with respect to dendritic cells and monocytes applying  
506 a deconvolution of damped weighted least squares (DWLS) method as described previously<sup>6</sup>.

#### 507 **Transcription factor and Pathway activities from RNA-seq data**

508 Transcription factor activities were inferred from RNA-seq data using prior knowledge as  
509 provided by Collection of Transcriptional Regulatory Interactions (CollectRI (Preprint at  
510 <https://doi.org/10.1101/2023.03.30.534849> (2023)), DECOUPLER v2.6.0), which provide a  
511 curated collection of 1,175 transcription factors. Briefly, *t*-values between two conditions  
512 (BPDCN DC cluster) were estimated using LIMMA. Transcription factor activities were  
513 estimated on *t*-values using weighted means and activities with  $p < 0.05$  were plotted (28  
514 transcription factors).

515 Pathway activities for curated pathways with weights for each interaction were estimated  
516 using Pathway RespOnsive GENes for activity inference (PROGENy<sup>64</sup>, gene signatures for  
517 14 pathways) on limma estimated *t*-values (as above).

518

#### 519 **Genome-wide DNA methylation profiling and data analysis**

520 Whole-genome DNA methylation analysis was carried out on all 54 cases of the study cohort  
521 employing the Illumina EPIC array at ATLAS Biolabs. Bioconductor R package MINIFI  
522 (v1.46.0) was used to further process raw IDATs that were previously generated from iScan.  
523 The quality of samples was checked by using mean detection *P*-values and only samples with  
524 *P*-values  $< 0.05$  were kept for further processing (five samples excluded). In addition,  
525 according to in-house bioinformatic QC pipelines (Glaser *et al.*, in preparation) was applied  
526 (one additional case excluded). Remaining samples were normalized using quantile  
527 normalization (function *preprocessQuantile*) and DNA methylation data predicted sex was  
528 compared to the actual sex. Samples, where the predicted sex did not match with the actual  
529 sex, were removed (four samples removed), leaving 45 samples for further analysis. DNA

530 methylation probes were quality filtered and probes with non-significant  $P$ -values were  
531 removed ( $P > 0.01$ ). Additionally, cross-reactive probes and BOWTIE2 multi-mapped probes  
532 were removed, and M- and beta-values of the remaining probes were extracted <sup>65</sup>.

533 Differentially methylated probes between two conditions were identified using a linear  
534 modeling approach as implemented in LIMMA. Generalized gene set testing on differentially  
535 methylated probes was performed by applying the *gsameth* function (MISSMETHYL package  
536 v1.34.0) against the REACTOME and/or HALLMARK gene sets (MSigDB v7.5).

537

### 538 **Comparative analysis with genome-wide DNA methylation data from different cell types**

539 To assess epigenetic differences between BPDCN and several cell types, we used data from  
540 different sources. Raw DNA methylation data (IDAT files) from B-lymphoid cells ( $n = 23$ ),  
541 naïve CD4+ ( $n = 23$ ), naïve CD8+ cells ( $n = 19$ ), granulocytes ( $n = 10$ ), monocytes ( $n = 24$ )  
542 and NK-cells ( $n = 20$ ) was retrieved from GEO accession GSE184269 <sup>20</sup>. Data were  
543 processed as described above with the exception that normalization was performed using  
544 subset-quantile within array normalization (*SWAN*, *MISSMETHYL*) and beta-values were  
545 extracted. DNA methylation profiles (beta-values) for dendritic cells ( $n = 6$ ; GEO accession  
546 GSE71837<sup>66</sup>) and hematopoietic stem cells ( $n = 5$ ; GEO accession GSE63409<sup>67</sup>) were  
547 download using GEOquery (v2.68.0).

548 Data sets were combined (including 45 BPDCN samples), probes matching to chromosome X  
549 or Y were removed, and only probes present in all studies were to remove unwanted variation  
550 between the data sets (batch effects). Unwanted technical variation was removed using a two-  
551 stage approach (RUVm). First, a standard limma analysis was performed to identify empirical  
552 control probes (ECPs). Next, the results from stage 1 were used to perform a second  
553 differential DNA methylation with RUV-4 (*RUVfit* function provided by the *MISSMETHYL*  
554 package) and adjusted beta-values were extracted. Region-level analysis was performed to  
555 call differentially methylated regions (DMRs) using adjusted beta-values between BPDCN

556 and dendritic cells using DMRcate (v2.13.0) and gene set testing was performed on DMRs  
557 with  $fdr < 0.1$  and absolute difference above 0.3 against REACTOME and HALLMARK  
558 gene sets using the *gsaregion* function (MISSMETHYL). Linkage of genes and enriched  
559 REACTOME pathways was performed for DMRs with  $fdr < 0.01$  and absolute difference  
560 above 0.3 using *enrichPathway* (REACTOMEPA, v1.44.0,  $q$ -value  $< 0.1$ ) and *cnetplot*  
561 (ENRICHPLOT, v1.20.0).

562

### 563 **Comparative analysis with genome-wide DNA methylation data from acute myeloid** 564 **leukemia**

565 Regarding epigenetic discrepancies that may aid in the distinction of borderline cases between  
566 BPDCN and its predominant differential diagnosis, acute myeloid leukemia (AML), we  
567 comparatively analyzed our dataset with a comprehensive, previously published AML cohort,  
568 incorporating 243 samples for which genetic subtype and genome-wide DNA methylation  
569 data was available (GEO accession GSE159907<sup>68</sup>). Data (IDAT files) was processed  
570 (including 45 BPDCN samples) as described above using SWAN to normalize the data and  
571 probes from chromosome X or Y were removed. Unwanted variation was removed using a  
572 two-stage approach (RUVm). First, Illumina negative control (INCs) data for EPIC arrays  
573 was extracted (411 probes) and differential DNA methylation analysis using RUV-inverse  
574 with INCs as negative control features was performed. Next, the results from stage 1 were  
575 used to perform a second differential DNA methylation with RUV-4 and adjusted M-values  
576 were extracted for further analysis. Region-level analysis was performed to call differentially  
577 methylated regions (DMRs) using adjusted M-values between BPDCN and AML using  
578 DMRcate (v2.13.0) and gene set testing was performed on DMRs with  $fdr < 0.1$  and absolute  
579 difference above 0.2 against REACTOME and HALLMARK gene sets using the *gsaregion*  
580 function (MISSMETHYL). Gene sets with  $P < 0.01$  were considered as significantly enriched.

581 Linkage of genes and enriched REACTOME pathways was performed for DMRs with  $\text{fdr} <$   
582 0.01 and absolute difference above 0.2 using *enrichPathway* ( $q\text{-value} < 0.1$ ) and *cnetplot*.

583

584

585

### 586 **Comparative analysis with genome-wide DNA methylation data from other entities**

587 Raw data files (IDAT) from AML (n = 316; GEO accession GSE159907), T-cell acute  
588 lymphoblastic leukemia (t-ALL, n = 156; GEO accession GSE155339<sup>69</sup>), and melanoma (n =  
589 450, TCGA project TCGA-SKCM) were downloaded and processed (including 45 BPDCN  
590 samples) as described above using SWAN to normalize the data; probes from chromosome X  
591 or Y were removed and beta-values were extracted. Additionally, beta-values for chronic  
592 myelomonocytic leukemia (CMML, n = 65; GEO accession GSE105420<sup>24</sup>) were downloaded  
593 and merged with the processed data. Unwanted variation was removed using a 2-stage  
594 approach as described in the section above ('Comparative analysis with genome-wide DNA  
595 methylation data from different cell types').

596

### 597 **Annotation of Methylated Regions**

598 Probe annotations were extracted using the R package  
599 ILLUMINAHUMANMETHYLATIONEPICANNO.ILM10B4.HG19 (v0.6.0). Probes annotated as  
600 'Island' were classified as CpG island (CGI) probes. Probes falling into 5' UTRs or within  
601 1,500 bp of the transcription start site were classified as promotor sites; sites within gene  
602 bodies or 3'UTRs were defined as gene body sites.

603

### 604 **Analysis of the tumor microenvironment by MethylCIBERSORT and** 605 **immunohistochemistry**



606 The cellular composition of the tumor microenvironment (TME) was assessed using  
607 MethylCIBERSORT as described. Beta values from raw IDATs and signature genes were  
608 deconvoluted according to immune cell populations<sup>18</sup>. Partitioning around medoids (PAM)  
609 was applied to identify immunologically hot versus cold immune tumors based on  
610 MethylCIBERSORT calculations and to assign the optimal cluster number in the data (testing  
611 from 2 to 10). Results obtained by MethylCIBERSORT were then validated through a  
612 correlative immunohistochemical assessment (IHC) of the T-cell and monocyte fraction of the  
613 TME. Antibodies and positivity cut-offs employed in the current study remain as described<sup>6</sup>.

614

#### 615 **DNA-methylation-based mitotic clock estimation**

616 To better comprehend the interaction between biological aging and molecular profiling in the  
617 light of the methylome, mitotic activity was estimated using epiCMIT. Mitotic clock was  
618 estimated on batch corrected beta-values for each sample and results were summarized per  
619 cohort<sup>27, 70</sup>.

620

#### 621 **FFPE-ATAC-seq**

622 ATAC-sequencing on FFPE tissue sections from four typical pDC-like BPDCN patients was  
623 performed as described<sup>71</sup>. Briefly, for nuclei isolation 20- $\mu$ m-thick sections were  
624 deparaffined and underwent subsequent enzyme digestion. Then, 50,000 isolated FFPE nuclei  
625 were used in each FFPE-ATAC reaction composed of Tn5-mediated transposition and T7 in  
626 vitro transcription. FFPE-ATAC libraries were then sequenced on an Illumina NovaSeq 6000  
627 platform at Novogene (Cambridge, UK) to a depth of at least 40 million 150-bp single-end or  
628 paired-end sequencing reads per library.

629

#### 630 **Statistical analysis**

631 If not reported otherwise, statistical analysis was performed using R (v4.3.0) and p-values  
632 were corrected using Benjamini-Hochberg correction. The following R packages were used:  
633 TIDYVERSE (v2.0.0)<sup>51</sup> for data handling and plotting; MAFTOOLS (v2.17.0)<sup>72</sup> to summarize,  
634 analyze, and visualize variant data; EnhancedVolcano (v1.18.0)  
635 (<https://github.com/kevinblighe/EnhancedVolcano>) plot volcano plots; COMPLEXHEATMAP  
636 (v2.16.0) and PHEATMAP (v1.0.12) to draw heatmaps; GGPUBR (v0.6.0) for box and violin-  
637 plots.

638 Intra-tumor heterogeneity was estimated on the entropy of somatic mutation (mDITHER-  
639 score) using DITHER (v1.0)<sup>73</sup>. Correlations were calculated using Spearman's rank  
640 correlation, if not stated differently.

641

#### 642 **Data availability**

643 Raw data for BPDCN samples have been downloaded from European Genome-phenome  
644 archive (EGA) under the previous accession number EGAS00001006166, additional cases  
645 were deposited under accession number EGAS00001007201, respectively. EPIC array data  
646 have been deposited in Gene Expression Omnibus (GEO) under accession number  
647 GSE230487.

648

#### 649 **Pseudonymization**

650 Processing of personal data for this study was performed pseudonymously by using a case-ID.  
651 Due to pseudonymization data backtracking specific to the individual is impossible. Only the  
652 initiators of the study (NG, AK, HW, JS) have access to a file that is separately stored  
653 (password-protected) containing the details on pseudonymization.

654

#### 655 **Declarations**

#### 656 **Ethics approval and consent to participate**

657 This retrospective study was approved by the ethics committee of the University of Lübeck  
658 (reference-no 18-311) and conducted in accordance with the declaration of Helsinki. Patients  
659 at the Reference center for Hematopathology have provided written informed consent  
660 regarding routine diagnostic and academic assessment, including genomic studies of their  
661 biopsy specimen alongside transfer of their clinical data.

662

### 663 **Competing interests**

664 The authors declare that they have no conflict of interest.

665

### 666 **Funding**

667 This work was supported by generous funding by the Stefan Morsch Foundation through a  
668 project grant (NG & HW). X.C. is supported by Swedish Research Council (2022-00658) and  
669 Swedish Cancer Foundation (21 1449Pj and 22 0491).

670

### 671 **Author contributions**

672 Study concept: NG, ACF, HM

673 Data collection: NG, AK, JS, HW, SS, PL, KN, KK, VB, HM, SS, XC, PX

674 Data analysis and creation of figures and tables: AK, NG, HW, VB, HB, NvB, MS,

675 XC, PX, FJ, HS

676 Initial Draft of manuscript: NG.

677 Critical revision and approval of final version: all authors.

678

### 679 **Acknowledgements**

680 The authors would like to thank Tanja Oeltermann for her skilled technical assistance. AK  
681 and HB acknowledge computational support from the OMICS compute cluster at the  
682 University of Lübeck.

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697 **References**

- 698 1. Arber DA, *et al.* The 2016 revision to the World Health Organization classification of  
699 myeloid neoplasms and acute leukemia. *Blood* **127**, 2391-2405 (2016).  
700
- 701 2. Chaperot L, *et al.* Identification of a leukemic counterpart of the plasmacytoid  
702 dendritic cells. *Blood* **97**, 3210-3217 (2001).  
703
- 704 3. Khoury JD, *et al.* The 5th edition of the World Health Organization Classification of  
705 Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia*  
706 **36**, 1703-1719 (2022).  
707
- 708 4. Renosi F, *et al.* Transcriptomic and genomic heterogeneity in blastic plasmacytoid  
709 dendritic cell neoplasms: from ontogeny to oncogenesis. *Blood Adv* **5**, 1540-1551  
710 (2021).  
711
- 712 5. Carmona-Saez P, *et al.* Metagene projection characterizes GEN2.2 and CAL-1 as  
713 relevant human plasmacytoid dendritic cell models. *Bioinformatics* **33**, 3691-3695  
714 (2017).  
715
- 716 6. Künstner A, *et al.* Integrative molecular profiling identifies two molecularly and  
717 clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm. *Blood*  
718 *Cancer Journal* **12**, 101 (2022).

- 719  
720 7. Laribi K, *et al.* Blastic plasmacytoid dendritic cell neoplasms: results of an  
721 international survey on 398 adult patients. *Blood Adv* **4**, 4838-4848 (2020).  
722
- 723 8. Togami K, *et al.* Sex-biased ZRSR2 mutations in myeloid malignancies impair  
724 plasmacytoid dendritic cell activation and apoptosis. *Cancer Discov*, (2021).  
725
- 726 9. Xiao W, *et al.* Plasmacytoid dendritic cell expansion defines a distinct subset of  
727 RUNX1-mutated acute myeloid leukemia. *Blood* **137**, 1377-1391 (2021).  
728
- 729 10. Zalmai L, *et al.* Plasmacytoid dendritic cells proliferation associated with acute  
730 myeloid leukemia: phenotype profile and mutation landscape. *Haematologica Online*  
731 **ahead of print**, (2020).  
732
- 733 11. Sangle NA, *et al.* Optimized immunohistochemical panel to differentiate myeloid  
734 sarcoma from blastic plasmacytoid dendritic cell neoplasm. *Mod Pathol* **27**, 1137-  
735 1143 (2014).  
736
- 737 12. Roos-Weil D, *et al.* Stem cell transplantation can provide durable disease control in  
738 blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European  
739 Group for Blood and Marrow Transplantation. *Blood* **121**, 440-446 (2013).  
740
- 741 13. Aoki T, *et al.* Long-term survival following autologous and allogeneic stem cell  
742 transplantation for blastic plasmacytoid dendritic cell neoplasm. *Blood* **125**, 3559-  
743 3562 (2015).  
744
- 745 14. Pemmaraju N, *et al.* Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. *N*  
746 *Engl J Med* **380**, 1628-1637 (2019).  
747
- 748 15. Capper D, *et al.* DNA methylation-based classification of central nervous system  
749 tumours. *Nature* **555**, 469-474 (2018).  
750
- 751 16. Koelsche C, *et al.* Sarcoma classification by DNA methylation profiling. *Nat Commun*  
752 **12**, 498 (2021).  
753
- 754 17. Pemmaraju N, *et al.* Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)  
755 Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies  
756 (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern  
757 Targeted Therapy Era. *Blood* **134**, 2723-2723 (2019).  
758
- 759 18. Chakravarthy A, *et al.* Pan-cancer deconvolution of tumour composition using DNA  
760 methylation. *Nat Commun* **9**, 3220 (2018).  
761
- 762 19. Guidry K, *et al.* DNA Methylation Profiling Identifies Subgroups of Lung  
763 Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age,  
764 and Clinical Outcome. *Clin Cancer Res* **28**, 3824-3835 (2022).  
765
- 766 20. Roy R, *et al.* DNA methylation signatures reveal that distinct combinations of  
767 transcription factors specify human immune cell epigenetic identity. *Immunity* **54**,  
768 2465-2480 e2465 (2021).  
769

- 770 21. Zhang X, *et al.* DNA methylation dynamics during ex vivo differentiation and  
771 maturation of human dendritic cells. *Epigenetics Chromatin* **7**, 21 (2014).  
772
- 773 22. Sapienza MR, *et al.* Newly-Discovered Neural Features Expand the Pathobiological  
774 Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm. *Cancers (Basel)* **13**,  
775 (2021).  
776
- 777 23. Tyner JW, *et al.* Functional genomic landscape of acute myeloid leukaemia. *Nature*  
778 **562**, 526-531 (2018).  
779
- 780 24. Palomo L, *et al.* DNA methylation profile in chronic myelomonocytic leukemia  
781 associates with distinct clinical, biological and genetic features. *Epigenetics* **13**, 8-18  
782 (2018).  
783
- 784 25. Liu Y, *et al.* The genomic landscape of pediatric and young adult T-lineage acute  
785 lymphoblastic leukemia. *Nat Genet* **49**, 1211-1218 (2017).  
786
- 787 26. Griffin GK, *et al.* Ultraviolet radiation shapes dendritic cell leukaemia transformation  
788 in the skin. *Nature* **618**, 834-841 (2023).  
789
- 790 27. Duran-Ferrer M, *et al.* The proliferative history shapes the DNA methylome of B-cell  
791 tumors and predicts clinical outcome. *Nat Cancer* **1**, 1066-1081 (2020).  
792
- 793 28. Yu M, Hazelton WD, Luebeck GE, Grady WM. Epigenetic Aging: More Than Just a  
794 Clock When It Comes to Cancer. *Cancer Res* **80**, 367-374 (2020).  
795
- 796 29. Bell CG, *et al.* DNA methylation aging clocks: challenges and recommendations.  
797 *Genome Biol* **20**, 249 (2019).  
798
- 799 30. Udtha M, Lee SJ, Alam R, Coombes K, Huff V. Upregulation of c-MYC in WT1-  
800 mutant tumors: assessment of WT1 putative transcriptional targets using cDNA  
801 microarray expression profiling of genetically defined Wilms' tumors. *Oncogene* **22**,  
802 3821-3826 (2003).  
803
- 804 31. Yin CC, *et al.* Integrated Clinical Genotype-Phenotype Characteristics of Blastic  
805 Plasmacytoid Dendritic Cell Neoplasm. *Cancers (Basel)* **13**, (2021).  
806
- 807 32. Bastidas Torres AN, *et al.* Whole-genome analysis uncovers recurrent IKZF1  
808 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm.  
809 *Genes Chromosomes Cancer* **59**, 295-308 (2020).  
810
- 811 33. Sapienza MR, *et al.* Blastic plasmacytoid dendritic cell neoplasm: genomics mark  
812 epigenetic dysregulation as a primary therapeutic target. *Haematologica* **104**, 729-737  
813 (2019).  
814
- 815 34. Sakamoto K, *et al.* Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic  
816 cell neoplasm: association with immunoblastoid cytomorphology, MYC expression,  
817 and drug response. *Leukemia* **32**, 2590-2603 (2018).  
818
- 819 35. Wang L, *et al.* ARID1A mutation in blastic plasmacytoid dendritic cell neoplasm.  
820 *Haematologica* **102**, e470-e472 (2017).

- 821  
822 36. Suzuki K, *et al.* Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell  
823 neoplasm. *Leukemia* **31**, 1629-1633 (2017).  
824  
825 37. Sapienza MR, *et al.* Molecular profiling of blastic plasmacytoid dendritic cell  
826 neoplasm reveals a unique pattern and suggests selective sensitivity to NF- $\kappa$ B pathway  
827 inhibition. *Leukemia* **28**, 1606-1616 (2014).  
828  
829 38. Zhou W, *et al.* DNA methylation loss in late-replicating domains is linked to mitotic  
830 cell division. *Nat Genet* **50**, 591-602 (2018).  
831  
832 39. Bormann F, *et al.* Cell-of-Origin DNA Methylation Signatures Are Maintained during  
833 Colorectal Carcinogenesis. *Cell Rep* **23**, 3407-3418 (2018).  
834  
835 40. Khanlari M, *et al.* Bone marrow clonal hematopoiesis is highly prevalent in blastic  
836 plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly  
837 patients. *Leukemia*, (2022).  
838  
839 41. Papaemmanuil E, *et al.* Clinical and biological implications of driver mutations in  
840 myelodysplastic syndromes. *Blood* **122**, 3616-3627; quiz 3699 (2013).  
841  
842 42. Batta K, *et al.* Divergent clonal evolution of blastic plasmacytoid dendritic cell  
843 neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin.  
844 *Leukemia* **35**, 3299-3303 (2021).  
845  
846 43. Cai X, *et al.* Runx1 loss minimally impacts long-term hematopoietic stem cells. *PLoS*  
847 *One* **6**, e28430 (2011).  
848  
849 44. Wu JN, Roberts CW. ARID1A mutations in cancer: another epigenetic tumor  
850 suppressor? *Cancer Discov* **3**, 35-43 (2013).  
851  
852 45. Hetzel S, *et al.* Acute lymphoblastic leukemia displays a distinct highly methylated  
853 genome. *Nat Cancer* **3**, 768-782 (2022).  
854  
855 46. McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling.  
856 *Cytokine* **75**, 38-50 (2015).  
857  
858 47. Straining R, Eighmy W. Tazemetostat: EZH2 Inhibitor. *J Adv Pract Oncol* **13**, 158-  
859 163 (2022).  
860  
861 48. Aung PP, *et al.* PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell  
862 Neoplasm. *Cancers (Basel)* **11**, (2019).  
863  
864 49. Witte HM, *et al.* Integrative genomic and transcriptomic analysis in plasmablastic  
865 lymphoma identifies disruption of key regulatory pathways. *Blood Adv*, (2021).  
866  
867 50. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor.  
868 *Bioinformatics* **34**, i884-i890 (2018).  
869  
870 51. Wickham H, *et al.* Welcome to the Tidyverse. *The Journal of Open Source Software*  
871 **4**, (2019).

- 872  
873 52. McKenna A, *et al.* The Genome Analysis Toolkit: a MapReduce framework for  
874 analyzing next-generation DNA sequencing data. *Genome Res* **20**, 1297-1303 (2010).  
875  
876 53. Sherry ST, *et al.* dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res*  
877 **29**, 308-311 (2001).  
878  
879 54. Cibulskis K, *et al.* Sensitive detection of somatic point mutations in impure and  
880 heterogeneous cancer samples. *Nat Biotechnol* **31**, 213-219 (2013).  
881  
882 55. McLaren W, *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* **17**, 122  
883 (2016).  
884  
885 56. Shyr C, Tarailo-Graovac M, Gottlieb M, Lee JJ, van Karnebeek C, Wasserman WW.  
886 FLAGS, frequently mutated genes in public exomes. *BMC Med Genomics* **7**, 64  
887 (2014).  
888  
889 57. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW.  
890 Cancer genome landscapes. *Science* **339**, 1546-1558 (2013).  
891  
892 58. Lawrence MS, *et al.* Mutational heterogeneity in cancer and the search for new  
893 cancer-associated genes. *Nature* **499**, 214-218 (2013).  
894  
895 59. Dobin A, *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21  
896 (2013).  
897  
898 60. Yin S, Wang X, Jia G, Xie Y. MIXnorm: normalizing RNA-seq data from formalin-  
899 fixed paraffin-embedded samples. *Bioinformatics* **36**, 3401-3408 (2020).  
900  
901 61. Ritchie ME, *et al.* limma powers differential expression analyses for RNA-sequencing  
902 and microarray studies. *Nucleic Acids Res* **43**, e47 (2015).  
903  
904 62. Kaspi A, Ziemann M. mitch: multi-contrast pathway enrichment for multi-omics and  
905 single-cell profiling data. *BMC Genomics* **21**, 447 (2020).  
906  
907 63. Villani AC, *et al.* Single-cell RNA-seq reveals new types of human blood dendritic  
908 cells, monocytes, and progenitors. *Science* **356**, (2017).  
909  
910 64. Schubert M, *et al.* Perturbation-response genes reveal signaling footprints in cancer  
911 gene expression. *Nat Commun* **9**, 20 (2018).  
912  
913 65. Pidsley R, *et al.* Critical evaluation of the Illumina MethylationEPIC BeadChip  
914 microarray for whole-genome DNA methylation profiling. *Genome Biol* **17**, 208  
915 (2016).  
916  
917 66. Vento-Tormo R, *et al.* IL-4 orchestrates STAT6-mediated DNA demethylation  
918 leading to dendritic cell differentiation. *Genome Biol* **17**, 4 (2016).  
919  
920 67. Jung N, Dai B, Gentles AJ, Majeti R, Feinberg AP. An LSC epigenetic signature is  
921 largely mutation independent and implicates the HOXA cluster in AML pathogenesis.  
922 *Nat Commun* **6**, 8489 (2015).



- 923  
 924 68. Giacomelli B, *et al.* DNA methylation epitypes highlight underlying developmental  
 925 and disease pathways in acute myeloid leukemia. *Genome Res* **31**, 747-761 (2021).  
 926  
 927 69. Roels J, *et al.* Aging of preleukemic thymocytes drives CpG island hypermethylation  
 928 in T-cell acute lymphoblastic leukemia. *Blood Cancer Discov* **1**, 274-289 (2020).  
 929  
 930 70. Horvath S. DNA methylation age of human tissues and cell types. *Genome Biol* **14**,  
 931 R115 (2013).  
 932  
 933 71. Zhang H, *et al.* Profiling chromatin accessibility in formalin-fixed paraffin-embedded  
 934 samples. *Genome Res* **32**, 150-161 (2022).  
 935  
 936 72. Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and  
 937 comprehensive analysis of somatic variants in cancer. *Genome Res* **28**, 1747-1756  
 938 (2018).  
 939  
 940 73. Li L, Chen C, Wang X. DITHER: an algorithm for Defining IntraTumor  
 941 Heterogeneity based on EntRopy. *Brief Bioinform* **22**, (2021).  
 942  
 943

944

945

946

947 **Table 1.** Baseline clinicopathological characteristics of the study group

Characteristics	BPDCN-C1 (n = 29)	BPDCN-C2 (n = 25)
Age (yrs.; median (range))	70 (15 - 91)	74 (42 - 90)
<b>Sex</b>		
Female	6 (21%)	8 (32%)
Male	23 (79%)	17 (68%)
<b>Manifestation</b>		
Skin	20 (69%)	14 (56%)
Bone marrow	8 (28%)	8 (32%)
0 EN-sites	3 (10%)	3 (12%)
1-2 EN sites	26 (90%)	19 (76%)
> 2 EN sites	-	3 (12%)
<b>Stage (Ann Arbor)</b>		
I/II	2/16 (13%)	3/16 (19%)
III/IV	14/16 (87%)	13/16 (81%)
<b>ECOG PS</b>		
0-1	8/10 (80%)	3/11 (27%)
≥2	2/10 (20%)	8/11 (73%)
<b>B-symptoms</b>		
No	6/14 (43%)	4/15 (27%)
Yes	8/14 (57%)	11/15 (73%)
<b>Immunohistochemistry</b>		
BPDCN-specific	29/29 (100%)	25/25 (100%)
CD56 <sup>+</sup>	29/29 (100%)	25/25 (100%)

CD123 <sup>+</sup>	29/29 (100%)	25/25 (100%)
TCL1	27/28 (96%)	17/23 (74%)
Immature lineage marker	21/29 (72%)	19/24 (79%)
CD34	1/29 (3%)	4/24 (17%)
TdT <sup>+</sup>	21/29 (72%)	16/23 (70%)
T-lineage markers	28/29 (96%)	24/25 (96%)
CD2 <sup>+</sup>	5/22 (23%)	7/16 (44%)
CD3 <sup>+</sup>	4/26 (15%)	5/23 (22%)
CD4 <sup>+</sup>	28/29 (96%)	23/25 (92%)
B-lineage marker CD79A <sup>+</sup>	23/28 (82%)	20/23 (87%)
Myeloid-lineage markers	24/26 (92%)	21/23 (91%)
CD33 <sup>+</sup>	24/26 (92%)	20/23 (87%)
CD117 <sup>+</sup>	2/26 (8%)	9/23 (39%)
MPO <sup>+</sup>	1*/28 (4%)	4*/23 (17%)
Ki-67 (median, range)	60% (30 – 90%)	50% (25 – 90%)
Abbreviations: BPDCN, blastic plasmacytoid dendritic cell neoplasm; ECOG, Eastern Cooperative Oncology Group; EN, extranodal; MPO, myeloperoxidase; yrs, years. *cases with concurrent other myeloid neoplasia (CMML or AML).		

948

949

950

951

952

953

954 **Figure Legends:**

955 **Figure 1. Epigenetic profiles of BPDCN and sorted hematopoietic cell populations.**

956 **a** First and second principal components of the 10,000 most variable DNA methylation sites  
 957 in BPDCN (C1 and C2) and various hematopoietic cell types (B = B lymphocytes, Granulo =  
 958 granulocytes, HSC = hematopoietic stem cells, iDC = immature dendritic cells, mDC =  
 959 mature dendritic cells, Mono = monocytes, NK = natural killer cells; ellipses show 95%  
 960 confidence intervals of multivariate normal distribution). **b** Average genome-wide DNA  
 961 methylation level (beta values) of BPDCN and various cell types and of BPDCN cluster C1  
 962 and C2. Individual estimates are shown as dots and cell type-specific distributions are shown  
 963 as box- and violin-plots; significant differences against BPDCN were assessed by unpaired  
 964 Wilcoxon test and significant levels are indicated by asterisks (\* =  $p < 0.05$ , \*\* =  $p < 0.01$ ,  
 965 and \*\*\* =  $p < 0.001$ ). **c** Enrichment analysis of differentially methylated regions (DMRs)

966 between BPDCN and dendritic cells (harmonic mean of the individual CpG FDRs < 0.01,  
967 absolute difference above 0.3) against HALLMARK and REACTOME gene sets. Only  
968 significant gene sets are shown (FDR < 0.1). **d** Network enrichment against REACTOME for  
969 DMRs (as in **c**); fold changes of DMRs (BPDCN vs DC) are color-scaled (red: higher DNA  
970 methylation in BPDCN; blue: higher DNA methylation in DC) and gene sets are denoted by  
971 light-brown nodes.

972

973 **Figure 2. BPDCN DNA methylation in comparison to AML, CMML, t-ALL and**  
974 **melanoma.**

975 **a** Visualization of the first and second principal components of the 10,000 most variable DNA  
976 methylation sites (ellipses show 95% confidence intervals of multivariate normal  
977 distribution). **b** Partial-least squares discriminant analysis (PLS-DA) of adjusted beta values. **c**  
978 First and second principal components of the comparison between BPDCN and AML  
979 (*RUNX1* wild-type and mutated samples highlighted differently). The four BPDCN cases  
980 falling inside the 95% confidence interval of the AML data are labeled. (d-j) a prototypical  
981 borderline case with both typical BPDCN as well as AML with pDC-like features; **d**  
982 Morphology of the neoplastic infiltrate within the lymph node resembles acute leukemia with  
983 polymorphic blast-like cells of variable size (H&E, 40x). **e** Uniform expression of CD123  
984 initially led to the inclusion of BPDCN into the differential diagnosis (CD123, 40x). **f** Further  
985 immunophenotypic work-up revealed several atypical features, reminiscent of AML with  
986 partial pDC phenotype, including variable expression of CD33 in a significant fraction of the  
987 malignant infiltrate (CD33, 40x), yet only partial expression of CD56 (**g**; CD56, 200x) and  
988 CD117 (**h**; CD117, 200x). **i** The bi-phenotypic character of the infiltrate is further underlined  
989 by a strong CD34 expression of a minor fraction of the blast-like cells alongside the vascular  
990 structures, resembling the pDC-like AML phenotype component, whereas the majority of  
991 blasts resemble phenotypically characteristic BPDCN cells. **j** Two-dimensional density plots

992 of average CpG site DNA methylation in BPDCN vs AML, CMML, t-ALL and melanoma  
993 (low density: orchid; high density: yellow/orange). **k** Average genome-wide DNA  
994 methylation level (beta values) of BPDCN, AML, CMML, t-ALL and melanoma; for BPDCN  
995 subcluster estimates are shown as well. **l** DNA-methylation-based mitotic clock (epiCMIT)  
996 estimates for each entity and BPDCN subtypes. **m** Network enrichment against REACTOME  
997 for DMRs between BPDCN and AML; fold changes are color-scaled (red: higher DNA  
998 methylation in BPDCN; blue: higher DNA methylation in AML) and gene sets are denoted by  
999 light-brown nodes. **n** Pathway enrichment against REACTOME gene sets of gene-associated  
1000 CpGs between BPDCN (blue) and AML (orange). **o** Pathway enrichment against  
1001 REACTOME gene sets of promotor-associated CpGs between BPDCN (blue) and AML  
1002 (orange).  
1003 If not stated differently, differences between BPDCN and the 4 other entities were assessed  
1004 by unpaired Wilcoxon test and significant levels are indicated by asterisks (\* =  $p < 0.05$ , \*\* =  
1005  $p < 0.01$ , and \*\*\* =  $p < 0.001$ ).

1006

1007

1008 **Figure 3. DNA methylation of tumor suppressor genes in BPDCN, AML and CMML.**

1009 **a** Average promoter DNA methylation (beta values) of tumor suppressor genes in BPDCN,  
1010 AML and CMML. **b** Average gene body DNA methylation (beta values) of tumor suppressor  
1011 genes in BPDCN, AML and CMML. **c** Average promoter and gene body DNA methylation in  
1012 selected tumor suppressor genes (for a complete representation of significantly divergent  
1013 TSGs see **Supplementary Figure 2**).

1014 Differences between BPDCN and the AML/CMML were assessed by unpaired Wilcoxon test  
1015 and significant levels are indicated by asterisks (\* =  $p < 0.05$ , \*\* =  $p < 0.01$ , and \*\*\* =  $p <$   
1016  $0.001$ ).

1017

1018 **Figure 4. Differential DNA methylation, expression and mutation patterns in BPDCN**  
1019 **subtypes C1 and C2.**

1020 **a** Top part of the heatmap shows mutational patterns of 14 genes previously identified as  
1021 significantly enriched between the two clusters <sup>6</sup>. The bottom part shows scaled beta values  
1022 (DNA methylation levels) of differentially methylated CpG sites ( $p < 0.0001$ ). **b** Volcano plot  
1023 of beta values showing  $\log_2$  fold-changes and p-values with gene annotations for significantly  
1024 different CpGs ( $p < 0.0001$ ). **c** Gene set enrichment analysis results of DNA methylation data  
1025 against REACTOME gene sets ( $p < 0.05$ ). **d** Volcano plot of expression profiles showing  $\log_2$   
1026 fold-changes and p-values with gene annotations for significant differentially expressed tumor  
1027 suppressors genes, oncogenes and genes involved in cell adhesion/cell cycle ( $p < 0.0001$ ). **e**  
1028 Gene set enrichment analysis of RNA-seq data against REACTOME gene sets ( $p_{adj} < 0.001$ ,  
1029 absolute enrichment  $> 0.3$ ). **f** Transcription factors with significantly different inferred  
1030 activity ( $p < 0.05$ ) in C1 (light blue) and C2 (dark blue). **g** Pathway activities in C1 (light  
1031 blue) and C2 (dark blue) with significantly different pathway activities shown in red font ( $p <$   
1032  $0.05$ ). **h,i** FFPE-ATAC-seq estimates of chromatin accessibility for *CDK6* and *STAT5A* for  
1033 four BPDCN cases belonging to subcluster C1. *CDK6* is located on the minus strand and  
1034 *STAT5B* on the plus strand, respectively.

1035

1036 **Figure 5. Tumor immune composition by MethylCIBERSORT identifies clusters of**  
1037 **divergent immunogenicity.**

1038 **a** DNA methylation data were deconvoluted according to immune cell populations  
1039 (MethylCIBERSORT). This revealed two different types of BPDCN (Treg and CD14 driven;  
1040 named IC1 and IC2, respectively) presenting with significantly differing immune cell subsets  
1041 in regard to the markers CD14 (monocytes/macrophages), CD19 (B-cells), CD4 (T-helper  
1042 cells) as well as fibroblasts, NK-cells and T-regulatory cells (T-regs). **b – e** A borderline  
1043 BPDCN/AML pDC-like case analyzed by MethylCIBERSORT and a comparative

1044 immunohistochemical assessment of the tumor microenvironment is presented. **b** H&E  
1045 staining reveals a cutaneous infiltrate covered by an intact epidermis. **c** Giemsa staining  
1046 reveals small blastoid cells with partly roundish occasionally monocytoid nuclei, small  
1047 nucleoli and weakly basophilic cytoplasm with increased mitotic activity. **d** Staining for  
1048 myeloid peroxidase reveals expected negativity in the malignant infiltrate alongside a few  
1049 positive, tumor-infiltrating myeloid cells. **e** However, CD14-Expression highlights both a  
1050 typical negative BPDCN population, as well as a relevant monocytoid population, including  
1051 few tumor-infiltrating monocytes alongside a larger subgroup of malignant cells. **f** Oncoplot  
1052 displays mutational patterns of 9 genes that were found to be more differentially mutated  
1053 between IC1 and IC2. Additionally, the heatmap illustrates TME cell proportions for each  
1054 individual sample. **g, h** Progression-free (PFS) and Overall survival (OS) analysis for patients  
1055 with available clinical follow-up according to IC1 vs IC2 identifies a significant inferior  
1056 prognostic impact for the IC1 subtype regarding PFS accompanied by a trend towards inferior  
1057 OS.

1058

1059

1060 **Figure 6. Impact of significant driver mutations and DNA methylation status of**  
1061 **epigenetic regulators on proliferative history and global CGI DNA methylation.**

1062 **(a)** Oncoplot displaying putative driver genes inferred by MUTSIGCV analysis in addition to  
1063 tumor mutational burden (TMB; upper bar plot),  $-\log_{10}$  p-values (left bars) and the number of  
1064 samples harboring mutations in a given gene (right bar). In total **6,065** bioinformatically  
1065 deleterious mutations, in **3,970** genes were observed. Of these indels and SNVs, 4,999 were  
1066 missense (82.4%), 321 nonsense (5.3%), 12 non-stop (0.2%) and 487 indel mutations (8.0%).  
1067 Mutation types are color-coded, and covariates are shown below for each sample (covariate  
1068 ‘Other’ refers to samples with tissue affected other than skin or bone marrow). **(b)** Analysis of  
1069 which significant mutational driver alterations may confer a higher or lower proliferative

1070 capacity to BPDCN cells. Statistically significant associations are delineated in red and blue,  
1071 respectively. (c) Comparative analysis regarding proliferative capacity in selected genes'  
1072 mutant and wild-type status. (d) A heatmap depicting the DNA methylation status of gene  
1073 promoter regions across a set of preselected epigenetic regulators associated directly and  
1074 indirectly with global DNA methylation, as described <sup>45</sup>. Average global DNA methylation  
1075 and CpG islands (CGI) are estimated per patient.

1076

1077

1078

1079

1080

1081

1082

1083

1084

1085

1086

1087 **Supplementary Figures:**

1088 **Supplementary Figure 1:** Deconvolution of bulk RNA-seq from the extended cohort of  
1089 BPDCN patients.

1090

1091 **Supplementary Figure 2:** Complete representation of promotor and gene body DNA  
1092 methylation of TSGs (according to Vogelstein *et al.*).

1093

1094 **Supplementary Figure 3:** Mutational landscape according to BPDCN C1 vs C2. a  
1095 significantly differentially mutated genes between C1 and C2. b TMB according to C1 vs C2

1096

1097 **Supplementary Figure 4:** Correlating the results from our MethylCIBERSORT approach  
1098 with the genomic landscape

1099

1100 **Supplementary Figure 5:** Mutational, epigenetic and immunohistochemical properties  
1101 according to ICs

1102

1103 **Supplementary Figure 6:** Quantitative estimation of tumor-infiltrating T-cells by **a** IHC and  
1104 **b** MethylCIBERSORT

1105

1106 **Supplementary Figure 7:** Unsupervised clustering of most variable methylated probes (n =  
1107 5,600) **a.** Heatmap **b.** TMB according to MethCs

1108

1109

1110

1111

1112

1113 **Supplementary Tables**

1114 **Supplementary Table 1: Variants**





1115 **Supplementary Table 2: MutSigCV**












1116 **Supplementary Table 3: Clinical data**




1117 **Supplementary Table 4: beta values for differentially methylated probes in the BPDCN**  
1118 **cohort.**


1119 **Supplementary Table 5: a) Correlation between DNA methylation and gene expression**  
1120 **for selected Genes (TSGs and oncogenes). b) Correlation between DNA methylation and**  
1121 **gene expression for the entire transcriptome.**















**a****b****c**





**a**

medRxiv preprint doi: <https://doi.org/10.1101/2023.07.28.23293273>; this version posted August 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

**b****c****d**